Drug Profile
Research programme: botulinum toxin A therapeutics - Revance Therapeutics
Alternative Names: RT401Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Revance Therapeutics
- Class Bacterial proteins; Bacterial toxins; Botulinum toxins
- Mechanism of Action Acetylcholine inhibitors; Glutamate antagonists; Neuromuscular blocking agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Rhinitis